Y-Mabs Therapeutics Financials
This page shows Y-Mabs Therapeutics (YMAB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
High-margin revenue is scaling, but development and corporate overhead still absorb more value than the business creates.
Between FY2023 and FY2024, reported losses widened from-$21.4M to-$29.7M . Yet operating cash burn improved from-$27.2M to-$15.7M , meaning the 2024 setback was harsher in accounting profit than in cash use, a pattern consistent with timing and non-cash items cushioning near-term liquidity.
FY2024 revenue of
The balance sheet remains liquidity-heavy: cash of
Financial Health Signals
Scored against emerging companies for FY2024. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Y-Mabs Therapeutics's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Y-Mabs Therapeutics scores 3.35, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($391.2M) relative to total liabilities ($27.9M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Y-Mabs Therapeutics passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Y-Mabs Therapeutics generates $0.53 in operating cash flow (-$15.7M OCF vs -$29.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Y-Mabs Therapeutics generated $87.7M in revenue in fiscal year 2024. This represents an increase of 3.4% from the prior year.
Y-Mabs Therapeutics's EBITDA was -$30.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 23.0% from the prior year.
Y-Mabs Therapeutics reported -$29.7M in net income in fiscal year 2024. This represents a decrease of 38.5% from the prior year.
Y-Mabs Therapeutics earned $-0.67 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 36.7% from the prior year.
Cash & Balance Sheet
Y-Mabs Therapeutics held $67.2M in cash against $0 in long-term debt as of fiscal year 2024.
Y-Mabs Therapeutics had 45M shares outstanding in fiscal year 2024. This represents an increase of 3.0% from the prior year.
Margins & Returns
Y-Mabs Therapeutics's gross margin was 82.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 3.7 percentage points from the prior year.
Y-Mabs Therapeutics's operating margin was -35.6% in fiscal year 2024, reflecting core business profitability. This is down 5.3 percentage points from the prior year.
Y-Mabs Therapeutics's net profit margin was -33.8% in fiscal year 2024, showing the share of revenue converted to profit. This is down 8.6 percentage points from the prior year.
Y-Mabs Therapeutics's ROE was -32.2% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 11.0 percentage points from the prior year.
Capital Allocation
Y-Mabs Therapeutics invested $49.0M in research and development in fiscal year 2024. This represents a decrease of 9.6% from the prior year.
YMAB Income Statement
| Metric | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.5M-6.6% | $20.9M-21.1% | $26.5M+43.5% | $18.5M-19.0% | $22.8M+14.4% | $19.9M-14.7% | $23.4M+14.2% | $20.5M |
| Cost of Revenue | $2.7M-11.3% | $3.0M-60.7% | $7.6M+239.9% | $2.2M-25.4% | $3.0M+43.7% | $2.1M+2.8% | $2.0M-21.4% | $2.6M |
| Gross Profit | $16.9M-5.8% | $17.9M-5.0% | $18.9M+16.3% | $16.2M-18.0% | $19.8M+10.9% | $17.8M-16.4% | $21.3M+19.4% | $17.9M |
| R&D Expenses | $11.1M-2.2% | $11.4M-7.0% | $12.2M+9.4% | $11.2M-9.5% | $12.3M-7.0% | $13.3M-0.9% | $13.4M-12.8% | $15.4M |
| SG&A Expenses | $11.3M-13.6% | $13.1M+5.8% | $12.4M-9.1% | $13.6M-21.0% | $17.2M+50.8% | $11.4M+2.6% | $11.1M+9.2% | $10.2M |
| Operating Income | -$5.6M+14.4% | -$6.5M-10.2% | -$5.9M+30.7% | -$8.6M+12.5% | -$9.8M-41.7% | -$6.9M-115.9% | -$3.2M+58.7% | -$7.7M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $7K+40.0% | $5K+100.7% | -$752K-317.3% | $346K+246.0% | $100K-37.5% | $160K-17.9% | $195K+4.3% | $187K |
| Net Income | -$3.2M+37.7% | -$5.2M+23.5% | -$6.8M+3.0% | -$7.0M+24.3% | -$9.2M-39.5% | -$6.6M-571.0% | -$988K+87.2% | -$7.7M |
| EPS (Diluted) | $-0.07+41.7% | $-0.12 | N/A | $-0.16+23.8% | $-0.21-40.0% | $-0.15 | N/A | $-0.18 |
YMAB Balance Sheet
| Metric | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $117.2M+4.1% | $112.6M-6.1% | $119.9M-0.8% | $120.9M-16.1% | $144.0M+16.8% | $123.3M-3.6% | $127.9M-0.8% | $128.9M |
| Current Assets | $91.8M+1.5% | $90.4M-8.2% | $98.5M-0.6% | $99.1M-21.9% | $126.8M+17.1% | $108.3M-2.6% | $111.1M-3.3% | $114.9M |
| Cash & Equivalents | $62.3M+3.3% | $60.3M-10.3% | $67.2M-1.3% | $68.1M-12.4% | $77.8M+2.7% | $75.7M-3.7% | $78.6M-9.2% | $86.6M |
| Inventory | $9.7M+21.6% | $8.0M+10.8% | $7.2M-24.5% | $9.6M+12.5% | $8.5M+0.6% | $8.4M+66.8% | $5.1M-28.8% | $7.1M |
| Accounts Receivable | $15.7M-11.3% | $17.7M-9.9% | $19.7M-1.1% | $19.9M-10.3% | $22.2M+7.8% | $20.6M-8.3% | $22.5M+19.0% | $18.9M |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $29.7M+28.3% | $23.2M-17.0% | $27.9M-2.1% | $28.5M-41.5% | $48.7M+101.9% | $24.1M-10.3% | $26.9M-6.4% | $28.7M |
| Current Liabilities | $22.9M+21.0% | $19.0M-20.0% | $23.7M-6.3% | $25.3M-41.8% | $43.5M+146.9% | $17.6M-12.5% | $20.1M-7.7% | $21.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $87.5M-2.2% | $89.5M-2.8% | $92.0M-0.5% | $92.4M-3.0% | $95.3M-3.9% | $99.2M-1.8% | $101.0M+0.8% | $100.2M |
| Retained Earnings | -$495.6M-0.7% | -$492.3M-1.1% | -$487.1M-1.4% | -$480.3M-1.5% | -$473.3M-2.0% | -$464.1M-1.4% | -$457.5M-0.2% | -$456.5M |
YMAB Cash Flow Statement
| Metric | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.7M+123.9% | -$6.9M-269.6% | -$1.9M+82.5% | -$10.7M-3678.9% | $298K+108.6% | -$3.5M+56.7% | -$8.0M-500.6% | -$1.3M |
| Capital Expenditures | $0-100.0% | $127K | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | $1.7M+123.5% | -$7.0M | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $0+100.0% | -$127K | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $332K+191.2% | $114K-88.4% | $986K+0.7% | $979K-44.3% | $1.8M+199.0% | $588K | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
YMAB Financial Ratios
| Metric | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.4%+0.7pp | 85.6%+14.5pp | 71.2%-16.7pp | 87.8%+1.0pp | 86.8%-2.7pp | 89.5%-1.8pp | 91.3%+4.0pp | 87.3% |
| Operating Margin | -28.7%+2.6pp | -31.3%-8.9pp | -22.4%+24.0pp | -46.4%-3.5pp | -42.9%-8.3pp | -34.7%-21.0pp | -13.7%+24.2pp | -37.9% |
| Net Margin | -16.6%+8.3pp | -24.9%+0.8pp | -25.6%+12.3pp | -37.9%+2.7pp | -40.6%-7.3pp | -33.3%-29.0pp | -4.2%+33.7pp | -37.9% |
| Return on Equity | -3.7%+2.1pp | -5.8%+1.6pp | -7.4%+0.2pp | -7.6%+2.1pp | -9.7%-3.0pp | -6.7%-5.7pp | -1.0%+6.8pp | -7.7% |
| Return on Assets | -2.8%+1.9pp | -4.6%+1.0pp | -5.7%+0.1pp | -5.8%+0.6pp | -6.4%-1.0pp | -5.4%-4.6pp | -0.8%+5.2pp | -6.0% |
| Current Ratio | 4.00-0.8 | 4.77+0.6 | 4.16+0.2 | 3.92+1.0 | 2.92-3.2 | 6.15+0.6 | 5.52+0.3 | 5.27 |
| Debt-to-Equity | 0.34+0.1 | 0.26-0.0 | 0.300.0 | 0.31-0.2 | 0.51+0.3 | 0.24-0.0 | 0.27-0.0 | 0.29 |
| FCF Margin | 8.5%+42.1pp | -33.7% | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Y-Mabs Therapeutics's annual revenue?
Y-Mabs Therapeutics (YMAB) reported $87.7M in total revenue for fiscal year 2024. This represents a 3.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Y-Mabs Therapeutics's revenue growing?
Y-Mabs Therapeutics (YMAB) revenue grew by 3.4% year-over-year, from $84.8M to $87.7M in fiscal year 2024.
Is Y-Mabs Therapeutics profitable?
No, Y-Mabs Therapeutics (YMAB) reported a net income of -$29.7M in fiscal year 2024, with a net profit margin of -33.8%.
What is Y-Mabs Therapeutics's EBITDA?
Y-Mabs Therapeutics (YMAB) had EBITDA of -$30.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Y-Mabs Therapeutics's gross margin?
Y-Mabs Therapeutics (YMAB) had a gross margin of 82.9% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Y-Mabs Therapeutics's operating margin?
Y-Mabs Therapeutics (YMAB) had an operating margin of -35.6% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Y-Mabs Therapeutics's net profit margin?
Y-Mabs Therapeutics (YMAB) had a net profit margin of -33.8% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Y-Mabs Therapeutics's return on equity (ROE)?
Y-Mabs Therapeutics (YMAB) has a return on equity of -32.2% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Y-Mabs Therapeutics's operating cash flow?
Y-Mabs Therapeutics (YMAB) generated -$15.7M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Y-Mabs Therapeutics's total assets?
Y-Mabs Therapeutics (YMAB) had $119.9M in total assets as of fiscal year 2024, including both current and long-term assets.
How much does Y-Mabs Therapeutics spend on research and development?
Y-Mabs Therapeutics (YMAB) invested $49.0M in research and development during fiscal year 2024.
What is Y-Mabs Therapeutics's current ratio?
Y-Mabs Therapeutics (YMAB) had a current ratio of 4.16 as of fiscal year 2024, which is generally considered healthy.
What is Y-Mabs Therapeutics's debt-to-equity ratio?
Y-Mabs Therapeutics (YMAB) had a debt-to-equity ratio of 0.30 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Y-Mabs Therapeutics's return on assets (ROA)?
Y-Mabs Therapeutics (YMAB) had a return on assets of -24.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Y-Mabs Therapeutics's cash runway?
Based on fiscal year 2024 data, Y-Mabs Therapeutics (YMAB) had $67.2M in cash against an annual operating cash burn of $15.7M. This gives an estimated cash runway of approximately 51 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Y-Mabs Therapeutics's Altman Z-Score?
Y-Mabs Therapeutics (YMAB) has an Altman Z-Score of 3.35, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Y-Mabs Therapeutics's Piotroski F-Score?
Y-Mabs Therapeutics (YMAB) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Y-Mabs Therapeutics's earnings high quality?
Y-Mabs Therapeutics (YMAB) has an earnings quality ratio of 0.53x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Y-Mabs Therapeutics?
Y-Mabs Therapeutics (YMAB) scores 75 out of 100 on our Financial Health Score, indicating strong standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.